Pharma 2016: One Year in Review

Lots of new things happened in the pharmaceutical industry in 2016. At, our mission is to make the pharmaceutical world simple and clear to everyone. We want our readers to have a privileged view on the key player in the healthcare system, and we do our best to keep things simple but highly accurate. The global healthcare environment is changing rapidly, so it is indispensable for life science and healthcare industry executives, researchers, investors, health policymakers and patients to be always updated.

Here is a selection of best pharma perspectives and news published here in this blog in the current year.

Pharmaceutical Products

At, we have covered some important viewpoints regarding pharmaceutical products in 2016, like the following:

Top 25 Pharmaceutical Products in 2015

Immuno-Oncology Upcoming Immunotherapies

World’s Top Ten Cancer Drugs by 2020

Top 10 Orphan Drugs and Their Economic Power

Hi-Tech Medicine: How Google and Apple Will Take Care of Our Health

Pharmaceutical Companies

We have reviewed and ranked the top companies in pharmaceutical and biotech industries:

Top 10 Pharmaceutical Companies 2016

World’s 10 Best Pharma and Biotech Companies of 2015

World’s Top 15 Biotech Companies 2016

The World’s Most Reputable Pharmaceutical Companies 2016

M&A in Pharma: Best 10 Deals in 2015-16

Top 10 Issues in Global Health Pharmaceutical Delivery Supply Chain

Clinical Research

In 2016, we have comprehensively focused on the topic of clinical research involving the efficacy and safety of medications and treatment options, like the following:

Approaches to Boost Clinical Trial Success

Approaches to Conquer Global CRA Shortage

Top 10 Global CROs in 2016

 Career Development in Pharma

Some exciting articles on career development for pharma professionals have been published at, like the following:

Medical Roles in the Industry: Biologist, Pharmacist and Pharmaceutical Physician

Pharmaceutical Sales Representatives – How to Stand Out in the Crowd?

The career section also includes the following two articles from our expert adviser Veronika Nemeth who will continue her collaboration with throughout 2017:

The Underrated Truth Behind First Impressions

Secret weapon to success

Healthcare sustainability and patient centricity

The other important viewpoints regarding the pharmaceutical industry that have been covered at in 2016 include the following:

Healthcare Sustainability: Here Is How Things Will Change

Top 10 Best Healthcare Systems in the World

Top 5 Causes of Drug Price Hike

Global Aging Pattern in 9 Graphs

Population Health & Personalized Medicine: Can they coexist?

Patients’ Associations and Pharmaceutical Companies: Joint Effort for Health

Patient Engagement: A Key Element in Pharmaceutical Marketing Strategy

Top 10 Medical Tourism Destinations Around the Globe

Global Healthcare Expenditure in 8 Graphs

We also critically reviewed few of the sources for healthcare and pharmaceutical updates:

Top 10 Pharma Blogs 2016

Best Websites for Pharmaceutical and Healthcare Updates


Top News 

In 2016, a lot of exciting news have shaken the pharmaceutical and biotech industry. We, at, have published many of those to quench the thirst of the professionals working in the pharmaceutical industry.

  • Company Business Updates

We have published a good number of news regarding pharma company updates, mergers and acquisitions, etc., like the following:

GSK Returns to War against Cancer

Boehringer Ingelheim Gives Global Development and Commercial Rights to Amgen for Investigational BiTE® Immuno-Oncology Drug for Multiple Myeloma

Quintiles and IMS Health Complete Merger

Novartis Separates its Pharmaceuticals Division into two business units: Novartis Oncology and Novartis Pharmaceuticals

Two Cardiovascular Collaborations Announced by Amgen and Arrowhead Pharmaceuticals

Roche launches a global network of cancer immunotherapy centers of research excellence (imCORE™)

Pfizer Acquires Bamboo Therapeutics and Aims to Become Industry Leader in Gene Therapy

Janssen Collaborates with TESARO, Inc., for Niraparib in Prostate Cancer

CHMP recommends Novartis drug Afinitor® for European Union approval

  • Regulatory Updates

In 2016, regulatory authorities in the pharmaceutical industry, like FDA and EMA, have approved a good number of medications. At, we have focused on many of those, including the following:

Pfizer Gets Positive CHMP Opinion for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for The Treatment of HR+/HER2- Metastatic Breast Cancer in Europe

BLINCYTO® (blinatumomab) is Approved by FDA for Use in Pediatric Patients with Philadelphia Chromosome-Negative Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

FDA Accepts Biologics License Application for Romosozumab, Amgen and UCB Announce

EMA and FDA accept Marketing applications of Roche for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis

KEYTRUDA® (pembrolizumab) of Merck Receives Positive CHMP Opinion for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

FDA Approves KEYTRUDA® (pembrolizumab) of Merck for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

FDA Accepts Supplemental Biologics License Application for Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Lilly And AstraZeneca Receive FDA Fast Track Designation For AZD3293 for Treating Early Alzheimer’s Disease

EMA Validates the Marketing Authorization Application for Avelumab for Treating Metastatic Merkel Cell Carcinoma

European Union Gives Approval to IBRANCE® (palbociclib) for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

Pfizer’s XALKORI® (Crizotinib) Receives Approval for the Treatment of Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in European Union

Takeda Gets Marketing Authorization for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma in Canada

Bristol-Myers Squibb and AbbVie Announce the Approval of Empliciti™ (elotuzumab)by European Commission for the Treatment of Multiple Myeloma

FDA Approves Prevnar 13® of Pfizer in Adults Age 18 Through 49

FDA Approves Vermox™ Chewable (Mebendazole) for Treating both Children and Adults with Whipworm and Roundworm Infections

Janssen Submits Marketing Authorisation Application to European Medicines Agency for Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1

European Union Approves Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (daclizumab) for the Treatment of Multiple Sclerosis

European Commission Approves the Immuno-Oncology Combination, Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen of Bristol-Myers Squibb, for Treatment of Advanced Melanoma

  • Clinical Trial results

We have reported results of some of the most important clinical trials in this year, including the following:

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Metformin and Sitagliptin for the Treatment of Type 2 Diabetes

Lynparza Phase III SOLO-2 trial reveals substantial progression-free survival benefit

Amgen Announces Top-Line Results from Phase 3 KYPROLIS® (Carfilzomib) CLARION Study in Patients with Newly Diagnosed Multiple Myeloma

Keytruda Shows Promise in Patients with Merkel Cell Carcinoma, A Rare Form of Skin Cancer

Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) assisted people with a particular type of lung cancer live significantly longer compared to chemotherapy, Phase III study showed

Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial for Patients with Multiple Myeloma

New Data on Opdivo (nivolumab) from Bristol-Myers Squibb Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients

New Research Details Published by Merck Scientists About the Early Development of Verubecestat

Merck’s Phase 3 Study Results Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published

New Clinical Results show Novartis’ Entresto™ reduced cardiovascular death or hospitalization for heart failure

Novartis announces positive phase III results showing effectiveness of BAF312 in patients with secondary progressive multiple sclerosis

Data presented by Novartis showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)

We have also covered news from few international congresses, including ASH and ESMO:

Top News from ASH 2016

Top News from ESMO 2016

For all of these news and views published in, Dr. Luca Dezzani, the editor and chief contributor of, have been included in the list of 10 top voices 2016 in healthcare by LinkedIn. In 2017, many other exciting and new sections will feature in this blog, including a new series on ‘Pharma companies at a glance’. The important career development section will also continue. Hopefully, you will be with us in 2017 too.

Pharma 2016: One Year in Review last edit: 2016-12-26T09:48:56+00:00 da igeahubcom

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar